Clinical and pathological assessments
HER2-POSITIVE BREAST CANCER
A pCR was observed in 23 of 43 patients (53.3%; 95% confidence interval [CI): 42.6–64.1), Pathological complete response (pCR) rate for all or each subtype of HER2-positive breast cancer. In addition, the clinical RR following completion of nab-PTX plus T-mab and P-mab was 92.8% (39/42).With the exception of one case because of unmeasurable lesions (Response to nab-PTX therapy. 